Cannabis: Rescheduling vs. De-scheduling
The Biden Administration’s recent announcement on cannabis reform featured pardons for simple marijuana possession. The announcement, which may impact over 6,500 Americans, also included a assurances that the President is initiating the administrative process to review how cannabis is scheduled under federal law.
While most agree that the current placement of cannabis in Schedule I of the Controlled Substances Act (CSA) is inaccurate due to the plant’s medicinal uses, people are divided on how to adjust its scheduling.
If cannabis were to be rescheduled, it would be recategorized from Schedule I to one of the less severe categories. But, if the federal government moves forward with de-scheduling cannabis, it would be removed from the CSA list altogether.
Current U.S. Drug Scheduling
Schedule I
Reserved for drugs that do not have a medical use and have a high potential for abuse, such as heroin, LSD, ecstasy, peyote, and for now, cannabis.
Schedule II
These substances have a high potential for abuse that can lead to severe and debilitating psychological and physical dependence, regardless of their medicinal benefits. The list includes cocaine, Vicodin, methamphetamine, Adderall, and fentanyl.
Schedule III
These substances have a moderate to a low propensity for addiction, such as ketamine, steroids, and testosterone.
Schedule IV
These substances are defined as drugs with a low potential for abuse and a low risk of dependence, such as Xanax, Ambien, and tramadol.
Schedule V
These substances are defined by a lower potential for abuse than the previous schedule and contain limited quantities of certain narcotics, such as Robitussin and Lyrica.
Problems with the Current Drug Schedule
Even with a cursory reading of the definitions, one can see the issues with the current scheduling. For example, it does not clearly define dependency, nor does it include tobacco and alcohol, which are responsible for a significant amount of deaths each year. Additionally, many would debate that cocaine and Xanax are far more addictive than cannabis, yet they are scheduled in a less severe category. Plus, research has continually proven the clear medical benefits of cannabis.
Since the current U.S. drug scheduling is restrictive, outdated, and vague, it is unlikely that rescheduling will do much for destigmatizing cannabis. Still, rescheduling or de-scheduling cannabis from the CSA would be a step in the right direction.
Stay tuned for future updates on the rescheduling or de-scheduling of cannabis in the United States!
How Can Point Seven Group Help?
The team of cannabis consultants and professionals at Point Seven Group have worked extensively in the U.S. and international cannabis markets and are familiar with the unique challenges of the cannabis industry. Follow us on social media to stay up to date with more cannabis industry updates!
- Wayzata moves to open city-run weed dispensary
The City of Wayzata is considering opening its own recreational cannabis dispensary sometime next year. On Tuesday, Wayzata’s City Council and mayor approved a contract with Colorado-based consulting firm Point7 to draft a business plan for the possible municipal dispensary. This would be the city’s … - Indiana Cannabis Legalization: 2024 Update
The Midwest has become a bustling hub for cannabis policy and industry, with states like Michigan, Illinois, and Ohio leading the charge in cannabis legalization. However, Indiana’s stance on cannabis remains a topic of significant interest and debate. As we delve into the status of … - Cannabis Expungement and Social Equity: Proven & Failed Concepts
In the realm of cannabis expungement and social equity, examining both proven and failed concepts is crucial for understanding the complexities of justice reform and equity within the cannabis industry. Proven concepts include initiatives such as automatic expungement processes, which streamline the clearance of certain …